Avastin helps cervical cancer patients

Share this article:

Avastin and chemotherapy added four months of survival among advanced cervical cancer patients. Medpage Today reported Friday that the study, published in the New England Journal of Medicine, showed median overall survival was 17 months with Avastin vs. 13.3 using only chemotherapy. Adding Avastin to platinum-based or nonplatinum therapy did not have a significant impact on results.

“Cervical cancer patients are often mothers with minor children. This is a major advance and clinical benefit to those patients," Memorial Sloan-Kettering Cancer Center's Carol Aghajaman told Medpage.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.